Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 91
Global haemophilia market is growing by high-single digit
Sales of recombinant coagulation factors
Recombinate®/Advate®
Strategic positioning of Novo Nordisk's
haemophilia portfolio
NovoSevenⓇ
Coagil VII®
KogenateⓇ/HelixateⓇ
Idelvion®
RixubisⓇ
Novo Nordisk
compound
Status
Strategic position
ObizurⓇ1
35
XynthaⓇ/RefactoⓇ
Eloctate®
NovoEight®
AlprolixⓇ
Benefix®
NovoSevenⓇ
Launched
Maintain market leadership
DKK
30
billion
NovoEight®
Launched
25
Establish presence in a competitive
market place
20
N8-GP
Phase 33
Contribute to market conversion
15
CAGR²: 4%
CAGR²: 10%
CAGR²: 16%
10
RefixiaⓇ/
REBINYN®
Approved 4
Contribute to new treatment paradigm
5
NovoThirteenⓇ
Launched
Launch first recombinant product
0
2011 2016
rFVIIa
2011 2016
2011 2016
rFVIII
rFIX
1 ObizurⓇ only indicated for acquired haemophilia
2 CAGR for 5-year period
changing
diabetes®
3 Submission of N8-GP expected Q1 2018 in the US and the EU
4 Refixia® is the brand name for N9-GP in the EU, and REBINYN® is the brand name
in the US
novo nordiskView entire presentation